Q4 & Full Year 2020 Preliminary Results Exceed Consensus Estimates and Reflect Continued Growth and Improvement Across Key Financial Metrics
Delivers on 2020 Outlook with Outperformance in Multiple Markets Across the Country
Strong Balance Sheet with More Than C$179 Million Raised Subsequent to Year-End; Well-Positioned for Additional Accretive Acquisitions and Targeted Growth CapEx in Markets Converting from Medical Only to Adult Use
NEW YORK--(BUSINESS WIRE)-- Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) is providing preliminary results for the fourth quarter and full year ended December 31, 2020. The Company is also issuing 2021 guidance.
“Our record breaking fourth quarter and full year performance was driven by continued revenue growth and margin expansion. We generated robust sequential and year-over-year increases in Combined Revenue, Gross Profit and Adjusted EBITDA,” said Nicholas Vita, CEO of Columbia Care. “We effectively navigated the challenges of the COVID-19 pandemic and, in spite of those headwinds, delivered an exceptional year as we exceeded every milestone target set forth in our 2020 outlook. Highlighting our position as an industry consolidator, we closed key acquisitions with The Green Solution and Project Cannabis and announced the transformational acquisition of Green Leaf Medical, which remains on target to close in the 3rd quarter of this year. Most notably, corporate profitability continued to expand as we further leverage our national scale. Including the full fourth quarter’s financial contribution of Project Cannabis, Columbia Care generated approximately $87M in Combined Revenue and $12M in Adjusted EBITDA. We have continued to see sequential revenue growth and margin improvements in the first quarter 2021, affirming Columbia Care’s position as the fastest growing top-tier multi-state operator.1 I am extremely proud of our team’s dedication to executing our growth strategy and delivering the highest-quality cannabis to our loyal patients and customers in the communities we serve.”
Fourth Quarter 2020 Financial Highlights2 (in $ thousands, excl. margin items) | |||||||||||||||
|
Q4 2020 |
Q3 2020 |
Q4 2019 |
% QoQ |
% YoY | ||||||||||
Combined Results |
|
|
| ||||||||||||
Revenue |
$ |
81,799 | $ |
54,162 | $ |
24,524 |
51% |
234% | |||||||
Adj. Gross Profit3 |
$ |
33,976 | $ |
21,157 | $ |
6,017 |
61% |
465% | |||||||
Adj. EBITDA |
$ |
9,468 | $ |
4,226 | $ |
(14,330) |
124% |
N/A | |||||||
Pro Forma Revenue | |||||||||||||||
Revenue |
$ |
86,876 |
N/A |
N/A |
N/A |
N/A | |||||||||
As Reported | |||||||||||||||
Revenue |
$ |
76,064 | $ |
48,703 | $ |
23,172 |
56% |
228% | |||||||
Gross Profit |
$ |
30,368 | $ |
17,231 | $ |
5,489 |
76% |
453% | |||||||
Adj. EBITDA |
$ |
8,303 | $ |
3,077 | $ |
(13,911) |
170% |
N/A | |||||||
Cash |
$ |
61,111 | $ |
42,142 | $ |
47,464 |
45% |
29% |
Full Year 2020 Financial Highlights2 (in $ thousands, excl. margin items) | |||||||||
|
FY 2020 |
FY 2019 |
% YoY | ||||||
Combined Results |
|
| |||||||
Combined Revenue |
$ |
197,909 | $ |
78,811 |
151% |
| |||
Combined Adj. Gross Profit3 |
$ |
76,109 | $ |
21,137 |
260% |
| |||
Combined Adj. EBITDA |
$ |
(905) | $ |
(47,355) |
98% |
| |||
Pro Forma Revenue | |||||||||
Revenue |
$ |
290,290 |
N/A |
N/A |
| ||||
As Reported | |||||||||
Revenue |
$ |
179,503 | $ |
77,459 |
132% |
| |||
Gross Profit |
$ |
65,772 | $ |
20,609 |
219% |
| |||
Adj. EBITDA |
$ |
(4,138) | $ |
(46,936) |
91% |
|